Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer

about

Stereotactic body radiotherapy for central lung tumors, yes we can!

P2860

Q52716693-683F142B-1F0F-450E-B451-ED2154F1948D

P2860

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer

Item

http://www.wikidata.org/entity/Q36636810

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@ast

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@en

type

Item

label

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@ast

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@en

prefLabel

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@ast

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@en

P1476

Radical thoracic radiotherapy ...... IV non-small cell lung cancer

@en

P2093

Jima Lv

http://www.w3.org/2001/XMLSchema#string

Jingbo Wang

http://www.w3.org/2001/XMLSchema#string

Jun Liang

http://www.w3.org/2001/XMLSchema#string

Luhua Wang

http://www.w3.org/2001/XMLSchema#string

Weibo Yin

http://www.w3.org/2001/XMLSchema#string

Xiaozhen Wang

http://www.w3.org/2001/XMLSchema#string

Zhe Ji

http://www.w3.org/2001/XMLSchema#string

Zhouguang Hui

http://www.w3.org/2001/XMLSchema#string

Zongmei Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study.

Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.

Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis

P304

182-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12305

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27042220

http://www.w3.org/2001/XMLSchema#string

P932

4773305

http://www.w3.org/2001/XMLSchema#string

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer

about

P2860

P2860

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932